The US had the largest pharmaceutical market revenue in 2017, and is expected...
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya to MorphoSys in these respective regions.
CPL: Product Development through Commercialisation
CPL develops and manufactures non-sterile liquid and semi-solid pharmaceutical products. We are solely focused on these dosage forms and have built our reputation as an industry-leading contract development and manufacturing organisation (CDMO).
Blockbuster immunology drugs facing patent expiry and biosimilar competition
Despite the highly competitive nature of the immunology drugs market there are several well-established blockbuster drugs that dominate in terms of revenue.
Liposomes protect, transport and release your drug at the right place and time. By this, a reduced dose achieves better efficacy and avoids side effects with a non-invasive application. A liposomal formulation can clearly improve the therapeutic index of your drug.
Russell Finex Provides Screening Solutions for New Milk Powder Production Plant
With a continued commitment to developing operations and a change in society for a healthier lifestyle leading to increased demand for milk powder products, Nestlé has invested in a new factory in Osorno, Chile.
DEA proposes rules to curb the manufacture of opioids
The US Drug Enforcement Agency (DEA) has proposed stricter rules for the manufacture of prescription opioids by drug makers.
Experts call for a review of pharma manufacturing processes
Industry experts called for a rethink of pharma industry paradigms around manufacturing orphan and cell products at DCAT Week 2018, which took place in New York City last month.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.